Oncology Central

CAR T therapy Yescarta get EU green light but meets resistance from NICE

0
Yescarta® (axicabtagene ciloleucel), a novel personalized CAR T cell therapy has been approved for use in Europe by the European Medicines Agency (EMA) but has received a draft negative guidance from NICE.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Articles

Insights

Interviews

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.